List of Hysingla Er drug patents

Hysingla Er is owned by Purdue Pharma Lp.

Hysingla Er contains Hydrocodone Bitartrate.

Hysingla Er has a total of 24 drug patents out of which 1 drug patent has expired.

Expired drug patents of Hysingla Er are:

  • US8529948

Hysingla Er was authorised for market use on 20 November, 2014.

Hysingla Er is available in tablet, extended release;oral dosage forms.

Hysingla Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.

The generics of Hysingla Er are possible to be released after 21 December, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8529948 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(5 months ago)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic